DelveInsight’s, “Acute Graft-versus-Host Disease Pipeline Insight, 2023,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Acute Graft-versus-Host Disease pipeline landscape. It covers the Acute Graft-versus-Host Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Acute Graft-versus-Host Disease Pipeline Report
- DelveInsight’s Acute Graft-versus-Host Disease pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Acute Graft-versus-Host Disease treatment.
- The leading companies working in the Acute Graft-versus-Host Disease Market include OncoImmune (Merck), MaaT Pharma, CSL Behring, Equillium, Roche, Cellect Biotechnology, Bristol-Myers Squibb, Takeda, Regimmune, AltruBio, Incyte Corporation, Chia Tai Tianqing Pharmaceutical, Kalytera Therapeutics, ASC Therapeutics, medac GmbH, and others.
- Promising Acute Graft-versus-Host Disease Pipeline Therapies in the various stages of development include Itacitinib, Corticosteroid, Tramadol/Diclofenac 50/50, GDC-8264, and others.
- September 2023: Grifols Therapeutics LLC announced a study of phase 3 clinical trials for SMT + PE-A 5%. This is a Phase 3, multicenter, randomized, controlled, parallel-group, open-label study to evaluate the effects of plasma exchange using human serum albumin 5% (PE-A 5%) in acute-on-chronic liver failure (ACLF) subjects. The study will involve approximately 40 study centers in the United States, Canada, and Europe with expertise in the management of subjects with ACLF.
- September 2023: Janssen Research & Development LLC announced a study of phase 3 clinical trials for Milvexian. The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of cardiovascular [CV] death, myocardial infarction [MI], and ischemic stroke).
Request a sample and discover the recent advances in Acute Graft-versus-Host Disease Treatment Drugs @ Acute Graft-versus-Host Disease Pipeline Report
In the Acute Graft-versus-Host Disease pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute Graft-versus-Host Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Acute Graft-versus-Host Disease Overview
Acute graft-versus-host disease (aGVHD) following allogeneic hematopoietic stem cell transplant (AHscT) is an immune triggered process, leading to profound immune dysregulation and organ dysfunction. The symptoms of Acute Graft-versus-host disease include maculopapular rash, hyperbilirubinemia with jaundice due to damage to the small bile ducts, leading to cholestasis; nausea, vomiting, and anorexia, watery or bloody diarrhea, and crampy abdominal pain.
Find out more about Acute Graft-versus-Host Disease Therapeutics Assessment @ Acute Graft-versus-Host Disease Preclinical and Discovery Stage Products
Acute Graft-versus-Host Disease Emerging Drugs Profile
- RGI-2001: Regimmune
- MaaT013: MaaT Pharma
Acute Graft-versus-Host Disease Pipeline Therapeutics Assessment
There are approx. 20+ key companies which are developing the Acute Graft-versus-Host Disease therapies. The Acute Graft-versus-Host Disease companies which have their Acute Graft-versus-Host Disease drug candidates in the most advanced stage, i.e. Phase III include, MaaT Pharma.
Learn more about the emerging Acute Graft-versus-Host Disease Pipeline Therapies @ Acute Graft-versus-Host Disease Clinical Trials Assessment
Scope of the Acute Graft-versus-Host Disease Pipeline Report
- Coverage- Global
- Acute Graft-versus-Host Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Acute Graft-versus-Host Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Acute Graft-versus-Host Disease Companies- OncoImmune (Merck), MaaT Pharma, CSL Behring, Equillium, Roche, Cellect Biotechnology, Bristol-Myers Squibb, Takeda, Regimmune, AltruBio, Incyte Corporation, Chia Tai Tianqing Pharmaceutical, Kalytera Therapeutics, ASC Therapeutics, medac GmbH, and others.
- Acute Graft-versus-Host Disease Pipeline Therapies- Itacitinib, Corticosteroid, Tramadol/Diclofenac 50/50, GDC-8264, and others.
Dive deep into rich insights for new drugs for Acute Graft-versus-Host Disease treatment, Visit @ Acute Graft-versus-Host Disease Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Acute Graft-versus-Host Disease: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Acute Graft-versus-Host Disease – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- MaaT013: MaaT Pharma
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- RGI-2001: Regimmune
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Itolizumab: Equillium
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Acute Graft-versus-Host Disease Key Companies
- Acute Graft-versus-Host Disease Key Products
- Acute Graft-versus-Host Disease- Unmet Needs
- Acute Graft-versus-Host Disease- Market Drivers and Barriers
- Acute Graft-versus-Host Disease- Future Perspectives and Conclusion
- Acute Graft-versus-Host Disease Analyst Views
- Appendix
For further information on the Acute Graft-versus-Host Disease pipeline therapeutics, reach out to Acute Graft-versus-Host Disease Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking